Quantitative Values and Clinical Interpretation

Dr. Melody addresses quantitative ctDNA interpretation beyond binary positive/negative results, citing colleague consultations about patients with fulminant imaging relapse but relatively low ctDNA values. She emphasizes that relapse confirmation by PET-CT takes precedence over absolute ctDNA numbers, though acknowledging situations where quantitative values provide meaningful clinical information requiring expert interpretation.

Dr. Roschewski explains that ctDNA correlates with tumor burden but not in one-to-one stoichiometric relationships. Certain lymphomas secrete disproportionate ctDNA amounts for poorly understood reasons - large, bulky anterior mediastinal tumors and primary mediastinal B-cell lymphoma produce significantly more ctDNA than corresponding tumor burdens in diffuse large B-cell lymphoma not otherwise specified. Mechanisms involve factors beyond tumor bulk, likely including clearance and secretion variations.

Quantitative monitoring enables individual patient trend following, serving as personal controls similar to M-spike or human chorionic gonadotropin monitoring in other malignancies. False-positive tests do not exclusively show low values - their recent publication demonstrated high detectable levels that did not progress to clinical relapse, eventually clearing spontaneously. Numbers provide kinetic information for individual patients, with stable or declining trends offering reassurance even when initially elevated.

All lymphomas demonstrate ctDNA value fluctuation, requiring trend interpretation rather than single-value decision-making. Dr. Roschewski anticipates quantitative discussions becoming more prominent as field experience matures, moving beyond binary interpretation toward nuanced kinetic monitoring approaches that account for individual patient baselines and temporal changes.

Both physicians conclude their comprehensive discussion emphasizing ctDNA's transformative potential for lymphoma care while acknowledging current limitations and ongoing research needs for optimal clinical integration across diverse lymphoma subtypes and treatment settings.